New Princeton lab gives skincare-focused biotech direct control over research behind its flagship rapalog serum, rather than renting it out.
Most young biotechs outsource their early research, borrowing lab time, equipment and staff from wherever they can get it cheaply. Rapalogix Health just did the opposite. The Carlsbad, California-based company, which is building a business around a still-emerging category it calls longevity-based skin health, has announced that it has opened dedicated laboratory space at Princeton Innovation Center BioLabs in New Jersey, moving a chunk of its research in-house for the first time.
The facility, a life-sciences incubator operated by BioLabs and founded by Princeton University, gives Rapalogix access to fully equipped wet and dry lab space, shared scientific equipment, on-site technical staff and a surrounding community of life-science companies and academic researchers, all without the time and capital it would normally take to build that infrastructure from scratch. The lab became operational on 17 August 2026 [1].
What the lab is actually for
Rapalogix’s research is built around rapalogs, a class of compounds tied to longevity signaling pathways in the body, applied specifically to skin biology rather than to the whole-body anti-aging space most people associate the term with. The company’s first commercial product, Re-Q Longevity Face Serum, is powered by a proprietary compound called RLX-201 and is already available through dermatology and aesthetic practices in the US.
From the new lab, the company’s research team plans to use 2D, 3D and more complex model systems to study how longevity pathways function specifically in skin tissue, map out the mechanisms behind its broader rapalog portfolio, test new formulations and generate the kind of proprietary data that future products will need to stand behind.
“Establishing our own laboratory is a deliberate step in how we build the evidence base for this category,” said Dr Rahul Mehta, CEO and co-founder of Rapalogix Health. “Generating data internally gives us direct control over the questions we pursue and the pace at which we pursue them, and it shortens the path from mechanistic insight to formulation. Princeton Innovation Center BioLabs gives us that capability alongside a community of scientists working on adjacent problems, and it lets us put capital into experiments rather than infrastructure.”
A category still being defined
Longevity-based skincare is a young enough field that its own scientists talk about it as something still taking shape, not a settled discipline with established playbooks.
“There is so much to uncover as we pioneer longevity science, which represents a profound paradigm shift from the traditional approach to antiaging,” said Dr Manpreet Randhawa, executive director of research and development at Rapalogix Health. “Having immediate access to fully equipped wet labs and a forward-thinking scientific community allows us to move swiftly from hypothesis to validation, creating the rigorous science needed to genuinely push longevity and healthspan forward.”
That framing – longevity and healthspan rather than antiaging – is doing real work in how the company positions itself. Traditional anti-aging skincare has largely sold appearance: fewer wrinkles, firmer texture, a younger look. Rapalogix bets that the same longevity science being applied to organs and cellular pathways elsewhere in the body can be pointed at skin specifically, treating it as living tissue whose functional decline can be measured and slowed, not just cosmetically masked.
On its face, a company opening a research lab isn’t dramatic news, but for a firm operating in a category that doesn’t yet have agreed-upon standards for what “longevity skincare” even means scientifically, owning the lab where that evidence gets generated is a meaningful bet on credibility. It signals that Rapalogix intends to compete on data rather than marketing claims, in a segment of the beauty and wellness industry that has historically leaned hard on the latter. Whether RLX-201 and the rapalog class more broadly can deliver measurable, functional improvements in aging skin is the question this lab now exists to answer, on the company’s own terms and its own timeline.
